@article{fdi:010094207,
  title = {{P}ulmonary {A}spergillosis : {E}pidemiology and unresolved diagnostic challenges-insights from a two-year retrospective cohort study in {M}arseille},
  author = {{P}ham, {T}. {Q}. and {D}elorme, {L}. and {C}ortaredona, {S}{\'e}bastien and {R}anque, {S}. and {M}enu, {E}.},
  editor = {},
  language = {{ENG}},
  abstract = {{O}bjective: {A}spergillus spp. are ubiquitous fungi that cause invasive pulmonary aspergillosis ({IPA}), chronic pulmonary aspergillosis ({CPA}), allergic bronchopulmonary aspergillosis ({ABPA}), and some other less common forms depending on the immune status of the host. {T}his study aimed to evaluate the epidemiology and clinical diagnosis of {A}spergillus-related diseases at the {U}niversity {H}ospital of {M}arseille ({AP}-{HM}). {M}ethods: {W}e performed a retrospective cohort study of patients treated at the {AP}-{HM} between {J}anuary 2022 and {D}ecember 2023. {A}spergillus-specific serologic tests ({I}g{G}, {I}g{E}) and galactomannan antigen ({GM}) tests were integrated with clinical, imaging data from patients' medical records. {D}iagnostic frameworks were established based on the standard diagnostic criteria to identify {IPA}, {CPA}, and {ABPA}. {R}esults: {O}f 2412 patients with {GM} testing, 46 (1.9 %) had {IPA}. {O}f 2889 patients with {A}spergillus-specific {I}g{G} testing, 16 (0.6 %) were diagnosed with {CPA}. {O}f 1779 patients with {A}spergillus-specific {I}g{E} testing, 46 (2.6 %) were diagnosed with {ABPA}. {W}e noted biotherapy (tocilizumab and oblinutuzumab) as potential emerging risk factors for {IPA}. {S}trikingly, only 10 of 46 patients with {ABPA} were treated by physicians, highlighting potential gaps in clinical practice and current diagnostic guidelines. {T}he 3-month case fatality rate was 46.7 % for {IPA}, 13.3 % for {CPA} and 0 for {APBA}. {D}espite treatment, 13 % of patients with {ABPA} experienced an exacerbation. {C}onclusions: {T}his study highlights the prevalence of {A}spergillus-related lung disease and the high 3-month mortality rate in {IPA} and {CPA} in {AP}-{HM}. {D}iscrepancies in {ABPA} diagnosis highlight the need for improved diagnostic algorithms that better reflect real-world clinical practice and address these challenges.},
  keywords = {{E}pidemiology ; {P}ulmonary aspergillosis ; {A}spergillus ; specific {I}g{G} ; specific {I}g{E} ; {G}alactomannan ; {D}iagnosis ; {FRANCE} ; {MARSEILLE}},
  booktitle = {},
  journal = {{R}espiratory {M}edicine},
  volume = {245},
  numero = {},
  pages = {108206 [9 p.]},
  ISSN = {0954-6111},
  year = {2025},
  DOI = {10.1016/j.rmed.2025.108206},
  URL = {https://www.documentation.ird.fr/hor/fdi:010094207},
}